Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period
Abstract
:1. Introduction
2. Materials and Methods
- 8200/3 for adenoid cystic carcinoma (AdCC)
- 8430/3 for mucoepidermoid carcinoma (MEC)
- 8525/3, 8140/3 and 8147/3 for adenocarcinoma
- 8070/3, 8071/3, 8072/3 and 8073/3 for squamous cell carcinoma (SCC)
- 8550/3 for acinar cell carcinoma (AcCC)
- 6940/3 and 8914/3 for carcinoma in pleomorphic adenoma (CPA)
3. Results
4. Discussion
4.1. Epidemiological Characteristics of Patients
4.2. Clinical Characteristics of Patients
4.3. Treatment Modalities
4.4. Overal Survival
4.5. Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
AcCC | acinic cell carcinoma |
AdCC | adenoid cystic carcinoma |
CPA | carcinoma in pleomorphic adenoma |
CT | chemotherapy |
MEC | mucoepidermoid carcinoma |
NCR | National Cancer Registry |
NHF | National Health Fund |
OS | overall survival |
RCT | radiochemotherapy |
RT | radiotherapy |
SCC | squamous cell carcinoma |
References
- Carlson, E.R.; Schlieve, T. Salivary Gland Malignancies. Oral Maxillofac. Surg. Clin. N. Am. 2019, 31, 125–144. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.D.; Meng, L.J.; Hou, T.T.; Huang, S.H. Tumours of the salivary glands in northeastern China: A retrospective study of 2508 patients. Br. J. Oral Maxillofac. Surg. 2015, 53, 132–137. [Google Scholar] [CrossRef] [PubMed]
- Stryjewska-Makuch, G.; Kolebacz, B.; Janik, M.A.; Wolnik, A. Increase in the incidence of parotid gland tumors in the years 2005–2014. Otolaryngol. Pol. 2017, 71, 29–34. [Google Scholar] [CrossRef]
- Gatta, G.; Guzzo, M.; Locati, L.D.; McGurk, M.; Prott, F.J. Major and minor salivary gland tumours. Crit. Rev. Oncol. Hematol. 2020, 152, 102959. [Google Scholar] [CrossRef]
- Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Anzai, Y.; Brizel, D.M.; Bruce, J.Y.; Busse, P.M.; Caudell, J.J.; Cmelak, A.J.; et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2020, 18, 873–898. [Google Scholar] [CrossRef]
- Bjorndal, K.; Krogdahl, A.; Therkildsen, M.H.; Overgaard, J.; Johansen, J.; Kristensen, C.A.; Homoe, P.; Sorensen, C.H.; Andersen, E.; Bundgaard, T.; et al. Salivary gland carcinoma in Denmark 1990-2005: A national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011, 47, 677–682. [Google Scholar] [CrossRef] [PubMed]
- Van Dijk, B.A.; Gatta, G.; Capocaccia, R.; Pierannunzio, D.; Strojan, P.; Licitra, L.; Group, R.W. Rare cancers of the head and neck area in Europe. Eur. J. Cancer 2012, 48, 783–796. [Google Scholar] [CrossRef] [PubMed]
- Guzzo, M.; Locati, L.D.; Prott, F.J.; Gatta, G.; McGurk, M.; Licitra, L. Major and minor salivary gland tumors. Crit. Rev. Oncol. Hematol. 2010, 74, 134–148. [Google Scholar] [CrossRef]
- Zurek, M.; Rzepakowska, A.; Jasak, K.; Niemczyk, K. The Epidemiology of Salivary Glands Pathologies in Adult Population over 10 Years in Poland-Cohort Study. Int. J. Environ. Res. Public Health 2021, 19, 179. [Google Scholar] [CrossRef]
- Wahlberg, P.; Anderson, H.; Biorklund, A.; Moller, T.; Perfekt, R. Carcinoma of the parotid and submandibular glands—A study of survival in 2465 patients. Oral Oncol. 2002, 38, 706–713. [Google Scholar] [CrossRef]
- Chan, S.A.; Van Abel, K.M.; Lewis, J.E.; Routman, D.M.; Garcia, J.J.; Karp, E.E.; Price, D.L.; Janus, J.R.; Kasperbauer, J.L.; Moore, E.J. Mucoepidermoid carcinoma of the parotid gland: Twenty-year experience in treatment and outcomes. Head Neck 2021, 43, 2663–2671. [Google Scholar] [CrossRef] [PubMed]
- El-Naggar, A.K.; Chen, J.K.C.; Grandis, J.R.; Takata, T.; Slootweg, P.J. (Eds.) World Health Organization Classification of Tumours of Head and Neck; IARC: Lyon, France, 2017.
- Di Villeneuve, L.; Souza, I.L.; Tolentino, F.D.S.; Ferrarotto, R.; Schvartsman, G. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front. Oncol. 2020, 10, 580141. [Google Scholar] [CrossRef] [PubMed]
- Bjorndal, K.; Krogdahl, A.; Therkildsen, M.H.; Overgaard, J.; Johansen, J.; Kristensen, C.A.; Homoe, P.; Sorensen, C.H.; Andersen, E.; Bundgaard, T.; et al. Salivary gland carcinoma in Denmark 1990-2005: Outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2012, 48, 179–185. [Google Scholar] [CrossRef] [PubMed]
- Radoi, L.; Barul, C.; Menvielle, G.; Carton, M.; Matrat, M.; Sanchez, M.; Pilorget, C.; Velten, M.; Stucker, I.; Luce, D.; et al. Risk factors for salivary gland cancers in France: Results from a case-control study, the ICARE study. Oral Oncol. 2018, 80, 56–63. [Google Scholar] [CrossRef]
- Horn-Ross, P.L.; Ljung, B.M.; Morrow, M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997, 8, 414–419. [Google Scholar] [CrossRef]
- Horn-Ross, P.L.; Morrow, M.; Ljung, B.M. Diet and the risk of salivary gland cancer. Am. J. Epidemiol. 1997, 146, 171–176. [Google Scholar] [CrossRef]
- Forrest, J.; Campbell, P.; Kreiger, N.; Sloan, M. Salivary gland cancer: An exploratory analysis of dietary factors. Nutr. Cancer 2008, 60, 469–473. [Google Scholar] [CrossRef]
- Koo, H.Y.; Han, K.; Shin, D.W.; Yoo, J.E.; Cho, M.H.; Jeon, K.H.; Kim, D.; Hong, S.; Jun, J.K. Alcohol Drinking Pattern and Risk of Head and Neck Cancer: A Nationwide Cohort Study. Int. J. Environ. Res. Public Health 2021, 18, 1204. [Google Scholar] [CrossRef]
- Sood, S.; McGurk, M.; Vaz, F. Management of Salivary Gland Tumours: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 2016, 130, S142–S149. [Google Scholar] [CrossRef]
- Westergaard-Nielsen, M.; Rosenberg, T.; Gerke, O.; Dyrvig, A.K.; Godballe, C.; Bjorndal, K. Elective neck dissection in patients with salivary gland carcinoma: A systematic review and meta-analysis. J. Oral Pathol. Med. 2020, 49, 606–616. [Google Scholar] [CrossRef]
- Kawakita, D.; Murase, T.; Ueda, K.; Kano, S.; Tada, Y.; Tsukahara, K.; Okami, K.; Onitsuka, T.; Fujimoto, Y.; Matoba, T.; et al. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: A multi-institutional analysis in Japan. Int. J. Clin. Oncol. 2020, 25, 1774–1785. [Google Scholar] [CrossRef] [PubMed]
- Subramaniam, N.; Gao, K.; Gupta, R.; Clark, J.R.; Low, T.H. Trends in parotidectomy over 30 years in an Australian tertiary care center. Head Neck 2020, 42, 2905–2911. [Google Scholar] [CrossRef]
- Caudell, J.J.; Gillison, M.L.; Maghami, E.; Spencer, S.; Pfister, D.G.; Adkins, D.; Birkeland, A.C.; Brizel, D.M.; Busse, P.M.; Cmelak, A.J.; et al. NCCN Guidelines(R) Insights: Head and Neck Cancers, Version 1.2022. J. Natl. Compr. Cancer. Netw. 2022, 20, 224–234. [Google Scholar] [CrossRef] [PubMed]
- Xiao, M.; Liu, J.; You, Y.; Yang, X.; Wang, Y. Primary squamous cell carcinoma of the parotid gland: Clinicopathological characteristics, treatment, and prognosis. Int. J. Oral Maxillofac. Surg. 2021, 50, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Chakrabarti, S.; Nair, D.; Malik, A.; Qayyumi, B.; Nair, S.; Agrawal, J.P.; Chaturvedi, P. Prognostic factors in parotid cancers: Clinicopathological and treatment factors influencing outcomes. Indian J. Cancer 2018, 55, 98–104. [Google Scholar] [CrossRef]
- Harbo, G.; Bundgaard, T.; Pedersen, D.; Sogaard, H.; Overgaard, J. Prognostic indicators for malignant tumours of the parotid gland. Clin. Otolaryngol. Allied Sci. 2002, 27, 512–516. [Google Scholar] [CrossRef]
- Israel, Y.; Rachmiel, A.; Gourevich, K.; Nagler, R. Mortality rates and prognostic factors in patients with malignant salivary tumors. Med. Oncol. 2019, 36, 65. [Google Scholar] [CrossRef]
- Kordzinska-Cisek, I.; Cisek, P.; Grzybowska-Szatkowska, L. The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy—A Single Institution Experience. Cancer Manag. Res. 2020, 12, 1047–1067. [Google Scholar] [CrossRef]
- Liu, Y.; Su, M.; Yang, Y.; Zhao, B.; Qin, L.; Han, Z. Prognostic Factors Associated with Decreased Survival in Patients with Acinic Cell Carcinoma of the Parotid Gland. J. Oral Maxillofac. Surg. 2016, 75, 416–422. [Google Scholar] [CrossRef]
- Neskey, D.M.; Klein, J.D.; Hicks, S.; Garden, A.S.; Bell, D.M.; El-Naggar, A.K.; Kies, M.S.; Weber, R.S.; Kupferman, M.E. Prognostic Factors Associated with Decreased Survival in Patients with Acinic Cell Carcinoma. JAMA Otolaryngol. Head Neck Surg. 2013, 139, 1195–1202. [Google Scholar] [CrossRef]
- Oliveira, L.R.; Soave, D.F.; Oliveira-Costa, J.P.; Zorgetto, V.A.; Ribeiro-Silva, A. Prognostic factors in patients with malignant salivary gland neoplasms in a Brazilian population. Asian Pac. J. Cancer Prev. 2011, 12, 363–368. [Google Scholar]
- Soffer, J.M.; Nassif, S.J.; Von Plato, M.; Chisholm, J.; O’Leary, M.A. Survival and prognostic factors of salivary gland malignant mixed tumor-not otherwise specified: A population-based analysis. Am. J. Otolaryngol. 2021, 42, 103135. [Google Scholar] [CrossRef] [PubMed]
- Terhaard, C.H.; Lubsen, H.; Van der Tweel, I.; Hilgers, F.J.; Eijkenboom, W.M.; Marres, H.A.; Tjho-Heslinga, R.E.; de Jong, J.M.; Roodenburg, J.L.; Dutch, H.; et al. Salivary gland carcinoma: Independent prognostic factors for locoregional control, distant metastases, and overall survival: Results of the Dutch head and neck oncology cooperative group. Head Neck 2004, 26, 681–693. [Google Scholar] [CrossRef] [PubMed]
- Yamada, S.I.; Kurita, H.; Kamata, T.; Kirita, T.; Ueda, M.; Yamashita, T.; Ota, Y.; Otsuru, M.; Yamakawa, N.; Okura, M.; et al. Significant prognostic factors affecting treatment outcomes of salivary gland carcinoma: A multicenter retrospective analysis. Odontology 2018, 106, 96–102. [Google Scholar] [CrossRef]
- Filho, O.V.O.; Rego, T.; Mendes, F.H.O.; Dantas, T.S.; Cunha, M.; Malta, C.E.N.; Silva, P.G.B.; Sousa, F.B. Prognostic factors and overall survival in a 15-year followup of patients with malignant salivary gland tumors: A retrospective analysis of 193 patients. Braz. J. Otorhinolaryngol. 2020, 88, 365–374. [Google Scholar] [CrossRef] [PubMed]
- The National Health Fund Data. Available online: http://www.nfz.gov.pl (accessed on 1 April 2022).
- The National Cancer Registry Data. Available online: http://onkologia.org.pl/ (accessed on 1 April 2022).
- Statistics Poland Data. Available online: http://www.stat.gov.pl (accessed on 1 April 2022).
- Pfisterer, M.J.; Vazquez, A.; Mady, L.J.; Khan, M.N.; Baredes, S.; Eloy, J.A. Squamous cell carcinoma of the parotid gland: A population-based analysis of 2545 cases. Am. J. Otolaryngol. 2014, 35, 469–475. [Google Scholar] [CrossRef]
- Rajasekaran, K.; Stubbs, V.; Chen, J.; Yalamanchi, P.; Cannady, S.; Brant, J.; Newman, J. Mucoepidermoid carcinoma of the parotid gland: A National Cancer Database study. Am. J. Otolaryngol. 2018, 39, 321–326. [Google Scholar] [CrossRef] [PubMed]
- Scherl, C.; Kato, M.G.; Erkul, E.; Graboyes, E.M.; Nguyen, S.A.; Chi, A.C.; Morgan, P.F.; Day, T.A. Outcomes and prognostic factors for parotid acinic cell Carcinoma: A National Cancer Database study of 2362 cases. Oral Oncol. 2018, 82, 53–60. [Google Scholar] [CrossRef]
- Zhan, K.Y.; Huang, A.T.; Khaja, S.F.; Bell, D.; Day, T.A. Predictors of survival in parotid adenocarcinoma not otherwise specified: A National Cancer Database study of 3155 patients. Head Neck 2016, 38, 1208–1212. [Google Scholar] [CrossRef]
- Andreoli, M.T.; Andreoli, S.M.; Shrime, M.G.; Devaiah, A.K. Radiotherapy in Parotid Acinic Cell Carcinoma: Does It Have an Impact on Survival? Arch. Otolaryngol. Head Neck Surg. 2012, 138, 463–466. [Google Scholar] [CrossRef]
- van Weert, S.; Valstar, M.; Lissenberg-Witte, B.; Bloemena, E.; Smit, L.; van der Wal, J.; Vergeer, M.; Smeele, L.; Leemans, C.R. Prognostic factors in acinic cell carcinoma of the head and neck: The Amsterdam experience. Oral Oncol. 2022, 125, 105698. [Google Scholar] [CrossRef] [PubMed]
- He, J.F.; Lin, Y.; Wang, B.; Zhu, W.Y.; Wei, D.; Zhu, H.Y. Analysis of the clinicopathological characteristics and prognosis of adenoid cystic carcinoma of the intraoral minor salivary glands: A retrospective study of 40 cases. Int. J. Oral Maxillofac. Surg. 2021, 50, 444–450. [Google Scholar] [CrossRef] [PubMed]
- Al-Mamgani, A.; van Rooij, P.; Sewnaik, A.; Tans, L.; Hardillo, J.A. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: Long-term outcomes, QoL assessment and review of the literature. Oral Oncol. 2012, 48, 278–283. [Google Scholar] [CrossRef] [PubMed]
- Hametoja, H.; Hirvonen, K.; Hagstrom, J.; Leivo, I.; Saarilahti, K.; Apajalahti, S.; Haglund, C.; Makitie, A.; Back, L. Early stage minor salivary gland adenoid cystic carcinoma has favourable prognosis. Virchows Arch. 2017, 471, 785–792. [Google Scholar] [CrossRef]
- Bruzgielewicz, A.; Osuch-Wojcikiewicz, E.; Majszyk, D.; Checinski, P.; Nyckowska, J.; Zawadzka, B.; Skowronska-Gardas, A.; Niemczyk, K. Adenoid cystic carcinoma of the head and neck—A 10 years experience. Otolaryngol. Polska 2011, 65, 6–11. [Google Scholar] [CrossRef]
- Martinez-Rodriguez, N.; Leco-Berrocal, I.; Rubio-Alonso, L.; Arias-Irimia, O.; Martinez-Gonzalez, J.M. Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: A meta-analytic study. Med. Oral Patol. Oral Cir. Bucal 2011, 16, e884–e889. [Google Scholar] [CrossRef]
- Gupta, A.; Koochakzadeh, S.; Neskey, D.M.; Nguyen, S.A.; Lentsch, E.J. Carcinoma ex pleomorphic adenoma: A review of incidence, demographics, risk factors, and survival. Am. J. Otolaryngol. 2019, 40, 102279. [Google Scholar] [CrossRef]
- Chen, M.M.; Roman, S.A.; Sosa, J.A.; Judson, B.L. Predictors of survival in carcinoma ex pleomorphic adenoma. Head Neck 2014, 36, 1324–1328. [Google Scholar] [CrossRef]
- Zhao, J.; Wang, J.; Yu, C.; Guo, L.; Wang, K.; Liang, Z.; Lou, J. Prognostic factors affecting the clinical outcome of carcinoma ex pleomorphic adenoma in the major salivary gland. World J. Surg. Oncol. 2013, 11, 180. [Google Scholar] [CrossRef]
- Luers, J.C.; Wittekindt, C.; Streppel, M.; Guntinas-Lichius, O. Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy. Acta Oncol. 2009, 48, 132–136. [Google Scholar] [CrossRef]
- Boahene, D.K.; Olsen, K.D.; Lewis, J.E.; Pinheiro, A.D.; Pankratz, V.S.; Bagniewski, S.M. Mucoepidermoid carcinoma of the parotid gland: The Mayo clinic experience. Arch. Otolaryngol. Head Neck Surg. 2004, 130, 849–856. [Google Scholar] [CrossRef] [PubMed]
- Janz, T.A.; Lentsch, E.J.; Nguyen, S.A.; Clemmens, C.S. Are demographics associated with mucoepidermoid or acinic cell carcinoma parotid malignancies in children? World J. Otorhinolaryngol. Head Neck Surg. 2019, 5, 222–227. [Google Scholar] [CrossRef] [PubMed]
- Byrd, S.A.; Spector, M.E.; Carey, T.E.; Bradford, C.R.; McHugh, J.B. Predictors of recurrence and survival for head and neck mucoepidermoid carcinoma. Otolaryngol. Head Neck Surg. 2013, 149, 402–408. [Google Scholar] [CrossRef] [PubMed]
- Scherl, C.; Haderlein, M.; Agaimy, A.; Mantsopoulos, K.; Koch, M.; Traxdorf, M.; Fietkau, R.; Grundtner, P.; Iro, H. Outcome and management of rare high-grade “salivary” adenocarcinoma: The important role of adjuvant (chemo)radiotherapy. Strahlenther. Onkol. 2019, 195, 1050–1059. [Google Scholar] [CrossRef]
- Huang, A.T.; Tang, C.; Bell, D.; Yener, M.; Izquierdo, L.; Frank, S.J.; El-Naggar, A.K.; Hanna, E.Y.; Weber, R.S.; Kupferman, M.E. Prognostic factors in adenocarcinoma of the salivary glands. Oral Oncol. 2015, 51, 610–615. [Google Scholar] [CrossRef] [PubMed]
- Deng, R.; Tang, E.; Yang, X.; Huang, X.; Hu, Q. Salivary adenocarcinoma, not otherwise specified: A clinicopathological study of 28 cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 113, 655–660. [Google Scholar] [CrossRef]
- Chen, M.M.; Roman, S.A.; Sosa, J.A.; Judson, B.L. Prognostic factors for squamous cell cancer of the parotid gland: An analysis of 2104 patients. Head Neck 2015, 37, 1–7. [Google Scholar] [CrossRef]
- Ying, Y.L.; Johnson, J.T.; Myers, E.N. Squamous cell carcinoma of the parotid gland. Head Neck 2006, 28, 626–632. [Google Scholar] [CrossRef]
- Lee, S.; Kim, G.E.; Park, C.S.; Choi, E.C.; Yang, W.I.; Lee, C.G.; Keum, K.C.; Kim, Y.B.; Suh, C.O. Primary squamous cell carcinoma of the parotid gland. Am. J. Otolaryngol. 2001, 22, 400–406. [Google Scholar] [CrossRef]
- Akhtar, K.; Ray, P.S.; Sherwani, R.; Siddiqui, S. Primary squamous cell carcinoma of the parotid gland: A rare entity. BMJ Case Rep. 2013, 2013, bcr2013009467. [Google Scholar] [CrossRef]
- Bergersen, P.J.; Kennedy, P.J.; Kneale, K.L. Metastatic tumours of the parotid region. Aust. N. Z. J. Surg. 1987, 57, 23–26. [Google Scholar] [CrossRef]
- Boukheris, H.; Curtis, R.E.; Land, C.E.; Dores, G.M. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: A population-based study in the United States. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2899–2906. [Google Scholar] [CrossRef] [PubMed]
- Mayer, M.; Thoelken, R.; Jering, M.; Märkl, B.; Zenk, J. Metastases of Cutaneous Squamous Cell Carcinoma Seem to be the Most Frequent Malignancies in the Parotid Gland: A Hospital-Based Study from a Salivary Gland Center. Head Neck Pathol. 2021, 15, 843–851. [Google Scholar] [CrossRef] [PubMed]
- Franzen, A.; Buchali, A.; Lieder, A. The rising incidence of parotid metastases: Our experience from four decades of parotid gland surgery. Incremento dell’incidenza di metastasi alla ghiandola parotide: Analisi della nostra esperienza in quattro decenni di chirurgia parotidea. Acta Otorhinolaryngol. Ital. 2017, 37, 264–269. [Google Scholar] [CrossRef] [PubMed]
- Fang, Q.; Wu, J.; Liu, F. Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid gland. BMC Cancer 2019, 19, 752. [Google Scholar] [CrossRef]
- Lin, W.-N.; Huang, H.-C.; Wu, C.-C.; Liao, C.-T.; Chen, I.H.; Kan, C.-J.; Huang, S.-F. Analysis of acinic cell carcinoma of the parotid gland—15 years experience. Acta Otolaryngol. 2010, 130, 1406–1410. [Google Scholar] [CrossRef]
- Antony, J.; Gopalan, V.; Smith, R.A.; Lam, A.K. Carcinoma ex pleomorphic adenoma: A comprehensive review of clinical, pathological and molecular data. Head Neck Pathol. 2012, 6, 1–9. [Google Scholar] [CrossRef]
- Patel, E.J.; Oliver, J.R.; Liu, C.; Tam, M.; Givi, B. Outcomes of carcinoma ex pleomorphic adenoma compared to de novo adenocarcinoma of major salivary glands. J. Surg. Oncol. 2021, 123, 446–455. [Google Scholar] [CrossRef]
- Mannelli, G.; Cecconi, L.; Fasolati, M.; Santoro, R.; Franchi, A.; Gallo, O. Parotid adenoid cystic carcinoma: Retrospective single institute analysis. Am. J. Otolaryngol. 2017, 38, 394–400. [Google Scholar] [CrossRef]
- Ferrell, J.K.; Mace, J.C.; Clayburgh, D. Contemporary treatment patterns and outcomes of salivary gland carcinoma: A National Cancer Database review. Eur. Arch. Otorhinolaryngol. 2019, 276, 1135–1146. [Google Scholar] [CrossRef]
- Chen, A.M.; Garcia, J.; Bucci, M.K.; Quivey, J.M.; Eisele, D.W. The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 138–143. [Google Scholar] [CrossRef] [PubMed]
- Shen, C.; Xu, T.; Huang, C.; Hu, C.; He, S. Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol. 2012, 48, 445–449. [Google Scholar] [CrossRef] [PubMed]
- Garden, A.S.; Weber, R.S.; Morrison, W.H.; Ang, K.K.; Peters, L.J. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int. J. Radiat. Oncol. Biol. Phys. 1995, 32, 619–626. [Google Scholar] [CrossRef]
- Duberge, T.; Benezery, K.; Resbeut, M.; Azria, D.; Minsat, M.; Ellis, S.; Teissier, E.; Zaccariotto, A.; Champetier, C.; Cowen, D. Adenoid cystic carcinoma of the head and neck: A retrospective series of 169 cases. Cancer Radiother. 2012, 16, 247–256. [Google Scholar] [CrossRef]
- Zbaren, P.; Zbaren, S.; Caversaccio, M.D.; Stauffer, E. Carcinoma ex pleomorphic adenoma: Diagnostic difficulty and outcome. Otolaryngol. Head Neck Surg. 2008, 138, 601–605. [Google Scholar] [CrossRef]
Years | 1999–2003 | 2004–2008 | 2009–2013 | 2014–2018 | All | p-Value |
---|---|---|---|---|---|---|
Total number of selected parotid gland cancers | 460 | 548 | 644 | 666 | 2318 | 0.027 |
Demographic characteristics | ||||||
Mean age ± SD | 57.9 ± 15.2 | 60.4 ± 16.5 | 63.1 ± 15.7 | 62.8 ± 16.4 | 61.3 ± 16.1 | 0.075 |
Women (%) | 209 (45.4%) | 248 (45.3%) | 274 (42.6%) | 313 (47%) | 1044 (45%) | 0.442 |
Men (%) | 251 (54.6%) | 300 (54.7%) | 370 (57.4%) | 353 (53%) | 1274 (55%) | |
Urban citizens (%) | 311 (67.6%) | 340 (62%) | 404 (62.7%) | 430 (64.6%) | 1485 (64%) | 0.256 |
Rural citizens (%) | 149 (32.4%) | 208 (38%) | 240 (37.3%) | 236 (35.4%) | 833 (36%) | |
Histopathological diagnosis | ||||||
Adenoid cystic carcinoma | 63 (13.7%) | 62 (11.3%) | 75 (11.7%) | 62 (9.3%) | 262 (11.3%) | 0.148 |
Mucoepidermoid carcinoma | 57 (12.4%) | 87 (15.9%) | 93 (14.4%) | 81 (12.2%) | 318 (13.7%) | 0.214 |
Adenocarcinoma | 104 (22.6%) | 118 (21.5%) | 104 (16.2%) | 128 (19.2%) | 454 (19.6%) | 0.031 |
Squamous cell carcinoma | 131 (28.5%) | 168 (30.7%) | 244 (37.9%) | 229 (34.4%) | 772 (33.3%) | 0.005 |
Acinar cell carcinoma | 30 (6.5%) | 45 (8.2%) | 59 (9.2%) | 66 (9.9%) | 200 (8.6%) | 0.228 |
Carcinoma in pleomorphic adenoma | 75 (16.3%) | 68 (12.4%) | 69 (10.7%) | 100 (15%) | 312 (13.5%) | 0.026 |
Clinical stage | ||||||
Regional | 264 (57.4%) | 308 (56.2%) | 342 (53.1%) | 384 (57.7%) | 1298 (56%) | 0.347 |
Locoregional | 156 (33.9%) | 181 (33%) | 231 (35.9%) | 212 (31.8%) | 780 (33.6%) | 0.472 |
Systemic | 40 (8.7%) | 59 (10.8%) | 71 (11%) | 70 (10.5%) | 240 (10.4%) | 0.616 |
Therapy | ||||||
Only surgery | 107 (23.3%) | 127 (23.2%) | 162 (25.2%) | 219 (32.9%) | 615 (26.5%) | <0.001 |
Only radiotherapy | 32 (7%) | 48 (8.8%) | 91 (14.1%) | 95 (14.3%) | 266 (11.5%) | <0.001 |
Surgery + radiotherapy | 243 (52.8%) | 274 (50%) | 259 (40.2%) | 200 (30%) | 976 (42.1%) | <0.001 |
Surgery + chemotherapy + radiotherapy | 37 (8%) | 38 (6.9%) | 51 (7.9%) | 28 (4.2%) | 154 (6.6%) | 0.022 |
Others | 41 (8.9%) | 61 (11.1%) | 81 (12.6%) | 124 (18.6%) | 307 (13.2%) | <0.001 |
Histopathology | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Adenocarcinoma | Squamous Cell Carcinoma | Acinar Cell Carcinoma | Carcinoma in Pleomorphic Adenoma | All |
---|---|---|---|---|---|---|---|
All patients | 262 | 318 | 454 | 772 | 200 | 312 | 2318 |
Demographic characteristics | |||||||
Mean age ± SD | 56.34 ± 15.9 | 56.4 ± 18.6 | 62.9 ± 13.3 | 67.6 ± 13.4 | 54.1 ± 19.3 | 57.4 ± 15.3 | 61.3 ± 16.1 |
Women | 155 (59.2%) | 146 (45.9%) | 184 (40.5%) | 248 (32.1%) | 128 (64%) | 183 (58.7%) | 1044 (45%) |
Men | 107 (40.8%) | 172 (54.1%) | 270 (59.5%) | 524 (67.9%) | 72 (36%) | 129 (41.3%) | 1274 (55%) |
Urban citizens | 192 (73.9%) | 205 (64.5%) | 295 (65%) | 470 (60.9%) | 121 (60.5%) | 202 (64.7%) | 1485 (64.1%) |
Rural citizens | 70 (26.1%) | 113 (35.5%) | 159 (35%) | 302 (39.1%) | 79 (39.5%) | 110 (35.3%) | 833 (35.9%) |
Clinical stage | |||||||
Regional | 174 (66.4%) | 190 (59.8%) | 236 (52%) | 305 (39.5%) | 157 (78.5%) | 236 (75.6%) | 1298 (56%) |
Locoregional | 57 (21.8%) | 113 (35.5%) | 148 (32.6%) | 366 (47.4%) | 36 (18%) | 60 (19.2%) | 780 (33.8%) |
Systemic | 31 (11.8%) | 15 (4.7%) | 70 (15.4%) | 101 (13.1%) | 7 (3.5%) | 13 (4.2%) | 237 (10.2%) |
Therapy | |||||||
Only surgery | 66 (25.4%) | 91 (28.6%) | 92 (20.3%) | 142 (18.4%) | 76 (38%) | 148 (47.4%) | 615 (26.5%) |
Only RT | 21 (8.1%) | 30 (9.4%) | 48 (10.6%) | 139 (18%) | 8 (4%) | 20 (6.4%) | 266 (11.5%) |
Surgery + RT | 138 (53.1%) | 159 (50%) | 209 (46%) | 263 (34.1%) | 104 (52%) | 103 (33%) | 976 (42.1%) |
Surgery + RCT | 19 (7.3%) | 21 (6.6%) | 33 (7.3%) | 63 (8.2%) | 5 (2.5%) | 13 (4.2%) | 154 (6.6%) |
Others | 18 (3.9%) | 17 (3.1%) | 72 (11.2%) | 165 (24.8%) | 7 (0.3%) | 28 (1.2%) | 307 (13.2%) |
OS | Median (Years) | 1-Year (%) | 5-Years (%) | 10-Years (%) | 20-Years (%) |
---|---|---|---|---|---|
All analysed parotid gland cancers | 5.6 | 80% | 51.7% | 41.1% | 28.1% |
Histopathological diagnosis | |||||
Acinar cell carcinoma | 18.3 | 97% | 81.1% | 72.6% | 47.3% |
Adenocarcinoma | 4.5 | 81.3% | 48.7% | 35.9% | 23.6% |
Adenoid cystic carcinoma | 14.9 | 91.6% | 75% | 58.4% | 42.7% |
Carcinoma in pleomorphic adenoma | 17.4 | 88.1% | 69.6% | 60.7% | 42.2% |
Mucoepidermoid carcinoma | 10.9 | 85.8% | 58.9% | 51.2% | 40.2% |
Squamous cell carcinoma | 1.6 | 65.2% | 27.6% | 18.5% | 10.3% |
Clinical stage | |||||
Regional | 13.5 | 90.8% | 69.3% | 57.5% | 41.8% |
Locoregional | 2.21 | 71.4% | 34% | 24.1% | 13.5% |
Systemic | 1 | 49.6% | 14% | 9.4% | 2.3% |
Therapy | |||||
Only surgery | 15.1 | 86.8% | 69.6% | 57.5% | 43.5% |
Only radiotherapy | 1.3 | 59% | 26% | 18.7% | 16.9% |
Surgery + radiotherapy | 9.2 | 89.2% | 60.5% | 49.2% | 31.7% |
Surgery + chemotherapy + radiotherapy | 2.5 | 83.8% | 28.4% | 15.2% | 7.8% |
Other treatment | 1.2 | 53.1% | 21.8% | 14.8% | 10.5% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Żurek, M.; Jasak, K.; Jaros, K.; Daniel, P.; Niemczyk, K.; Rzepakowska, A. Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period. Int. J. Environ. Res. Public Health 2022, 19, 10247. https://doi.org/10.3390/ijerph191610247
Żurek M, Jasak K, Jaros K, Daniel P, Niemczyk K, Rzepakowska A. Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period. International Journal of Environmental Research and Public Health. 2022; 19(16):10247. https://doi.org/10.3390/ijerph191610247
Chicago/Turabian StyleŻurek, Michał, Kamil Jasak, Karolina Jaros, Piotr Daniel, Kazimierz Niemczyk, and Anna Rzepakowska. 2022. "Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period" International Journal of Environmental Research and Public Health 19, no. 16: 10247. https://doi.org/10.3390/ijerph191610247